COVID-19 Microbiota

11 JAN 2021: Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 (Gut)
“Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses. Furthermore, the gut microbiota dysbiosis after disease resolution could contribute to persistent symptoms, highlighting a need to understand how gut microorganisms are involved in inflammation and COVID-19.”

25 FEB 2021: Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? (Gut Pathogens)
“Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.”

20 APR 2021: From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis (Mediators of Inflammation)
“the importance of the gut microbiota composition in the lung immune system and ACE2 expression could be valuable to provide optimal therapeutic approaches for SARS-CoV-2 and to preserve the symbiotic relationship of the microbiota with the host.”

23 JUN 2022: The human microbiome and COVID-19: A systematic review (PLOS ONE)
“The human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. Further research to elucidate the effect of alternation of the human microbiome in disease pathogenesis is warranted.”

20 SEP 2021: Gut microbiota, inflammation, and molecular signatures of host response to infection (Journal of Genetics and Genomics)
“Overall, our multi-omics analyses suggest that gut microbiota composition and function are closely related to inflammation and molecular signatures of host response to infection among healthy individuals. These results may provide novel insights into the cross-talk between gut microbiota and host immune system.”

27 SEP 2021: Lung microbiota and COVID-19 severity (nature microbiology)

14 OCT 2021: Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential (Frontiers in Immunology)
“we discuss the available data related to the role of the gut microbiome in the development and progression of COVID-19. We provide mechanistic insights into early data with a focus on immunological crosstalk and the microbiome’s potential as a biomarker and therapeutic target.”

21 OCT 2021: Microbiota and compartment matter in the COVID-19 response (Nature)

DEC 2021: The intestinal microbiota and improving the efficacy of COVID-19 vaccinations (Journal of Functional Foods)
“In this narrative review, we discuss the immune responses to SARS-CoV-2, how COVID-19 vaccines elicit protective immune responses, gut dysbiosis involvement in inefficacy and adverse effects of COVID-19 vaccines and the modulation of the gut microbiota by functional foods to improve COVID-19 vaccine immunisations.”

29 DEC 2021: Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters (Gut Microbes)
“alteration of the gut microbiota correlates with disease severity in hamsters making this experimental model valuable for the design of interventional, gut microbiota-targeted, approaches for the control of COVID-19.”

26 JAN 2022: Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome (Gut)
“These findings provided observational evidence of compositional alterations of gut microbiome in patients with long-term complications of COVID-19. Further studies should investigate whether microbiota modulation can facilitate timely recovery from post-acute COVID-19 syndrome.”

9 FEB 2022: Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events (BMJ Gut)
“Our study has identified specific gut microbiota markers in association with improved immune response and reduced adverse events following COVID-19 vaccines. Microbiota-targeted interventions have the potential to complement effectiveness of COVID-19 vaccines.”

29 APR 2022: Could SARS-CoV-2 Have Bacteriophage Behavior or Induce the Activity of Other Bacteriophages (Vaccines)
“In order to further support these findings, in the present work, cultures of bacteria from the human microbiome and SARS-CoV-2 were analyzed by electron and fluorescence microscopy. The images presented in this article, in association with the nitrogen (15N) isotope-labeled culture medium experiment, suggest that SARS-CoV-2 could also infect bacteria in the gut microbiota, indicating that SARS-CoV-2 could act as a bacteriophage.”

29 APR 2022: Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions (Nature)
”we discuss the potential mechanisms by which microbiota-derived metabolites or components modulate the host immune responses to SARS-CoV-2 infection. Finally, we review and discuss a variety of possible microbiota-based prophylaxes and therapies for COVID-19 and PACS, including fecal microbiota transplantation (FMT), probiotics, prebiotics, microbiota-derived metabolites, and engineered symbiotic bacteria. This treatment strategy could modulate host microbiota and mitigate virus-induced inflammation.”

22 AUG 2022: Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show? (Clinical Nutrition)
“Further research is required to discern the role of the microbiome in the gut-lung axis and the role of probiotics in the prevention and treatment of SARS-CoV-2 and COVID-19 and the modulation of the gut and lung microbiomes.”